CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study

Blood Cancer J. 2023 Mar 24;13(1):44. doi: 10.1038/s41408-023-00813-x.

Jiahua Niu^#^{1

2}, Huiying Qiu^#^{1

2}, Fang Xiang^#³, Lin Zhu³, Jun Yang^{1

2}, Chongmei Huang^{1

2}, Kun Zhou^{1

2}, Yin Tong^{1

2}, Yu Cai^{1

2}, Baoxia Dong^{1

2}, Yuan Lu³, Xuedong Sun³, Liping Wan^{1

2}, Xueying Ding⁴, Haopeng Wang⁵, Xianmin Song^{6

7}

¹ Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
² Engineering Technology Research Center of Cell Therapy and Clinical Translation, Shanghai Science and Technology Committee (STCSM), Shanghai, China.
³ Hrain Biotechnology, Shanghai, China.
⁴ Engineering Technology Research Center of Cell Therapy and Clinical Translation, Shanghai Science and Technology Committee (STCSM), Shanghai, China. dingxueying@126.com.
⁵ School of Life Science and Technology, Shanghai Tech University, Shanghai, China. wanghp@shanghaitech.edu.cn.
⁶ Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. shongxm@sjtu.edu.cn.
⁷ Engineering Technology Research Center of Cell Therapy and Clinical Translation, Shanghai Science and Technology Committee (STCSM), Shanghai, China. shongxm@sjtu.edu.cn.

^# Contributed equally.

No abstract available

Publication types